Search

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval of new drugs and new indications in multiple myeloma clinical trials.

… Thursday, August 8, 2024 A Q&A with MSK Experts  MSK played a central role in the U.S. Food and Drug Administration (FDA)  Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an intermediate clinical endpoint for accelerated approval

Memorial Sloan Kettering Cancer Center (MSK) is ranked the number one hospital in the world for oncology according to Newsweek’s World’s Best Specialized Hospitals 2026 list.

… Thursday, October 30, 2025 Memorial Sloan Kettering Cancer Center (MSK) is ranked the number one hospital in the world for oncology according to  Newsweek’s   World’s Best Specialized Hospitals 2026 list. “Earning the distinction as the world’s top hospital for oncology is a profound honor that reflects

Memorial Sloan Kettering’s Vivian Strong, MD, FACS, addressed peers from around the world in May 2025 at the 16th Annual International Gastric Cancer Congress. Dr. Strong, a surgeon and MSK’s Iris Cantor Chair in Honor of Dr. Sidney Winawer, presented, “Gastric Cancer: A Global Fight for Innovation, the U.S. Perspective,” as the meeting’s Jin Pok Kim Lecturer.

… Thursday, May 8, 2025 Memorial Sloan Kettering’s  Vivian Strong, MD, FACS , addressed peers from around the world in May 2025 at the 16 th Annual International Gastric Cancer Congress. Dr. Strong, a surgeon and MSK’s Iris Cantor Chair in Honor of Dr. Sidney Winawer, presented, “Gastric Cancer: A Global

The first large study of its kind has found that having a healthy microbiota before starting the process of a bone marrow transplant using a patient’s own cells (autologous) leads to fewer complications after the procedure.

… Thursday, March 18, 2021 A patient’s health after a stem cell or bone marrow transplant (BMT) can depend on the bacteria in their gut. The trillions of microorganisms living there are also known as the microbiota. They can be damaged or wiped out by cancer treatments, leaving patients with severe intestinal

In a study published in the New England Journal of Medicine (NEJM), an MSK team report that they have found what enables cancer cells to become resistant to the experimental drug pirtobrutinib.

… Thursday, February 24, 2022 Since the first targeted therapies for blood cancer were developed more than 20 years ago, doctors and scientists have observed that many patients who respond well to these drugs initially end up developing resistance to them over time. There is an assumption among scientists

Children, teens, and young adults with leukemia that have stopped responding to chemotherapy are the first eligible to receive the new treatment.

… Wednesday, August 30, 2017 Summary A novel form of immunotherapy called CAR T is now an FDA-approved option for people with acute lymphoblastic leukemia (ALL) that has stopped responding to chemotherapy. Our scientists played several key roles in CAR T cell therapy development. In what is being hailed

Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program. MSK physicians and scientists are involved in notable research to be presented at the meeting.

… Wednesday, May 27, 2020 Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program . The online meeting will provide an engaging lineup of scheduled and on-demand scientific content including a plenary session

The FDA has granted full approval to the targeted therapy selpercatinib (Retevmo®) for treating thyroid cancers that have certain changes in a gene called RET. Learn about MSK’s role in the development of this drug and about how patients may benefit.

… Wednesday, July 10, 2024 On June 12, 2024, the US Food and Drug Administration (FDA) granted full approval to the targeted therapy  selpercatinib (Retevmo ® ) for treating adult and pediatric patients 2 years and older with advanced or metastatic  thyroid cancers that have certain changes in a gene called

Learn more about the new FDA-approved drug repotrectinib (AugtyroTM), which targets ROS1 fusions in lung cancer and other cancer types.

… Wednesday, January 10, 2024 Ingrid Adams, now 68, has been coping with metastatic lung cancer for more than a decade. Standard treatment — including chemotherapy and radiation therapy — kept her disease under control for a while, but the cancer continued to spread. Everything changed when she came to

Obtenga más información sobre el nuevo fármaco aprobado por la FDA, repotrectinib (AugtyroTM), que ataca las fusiones de ROS1 en el cáncer pulmonar y otros tipos de cáncer.

… Wednesday, January 10, 2024 Ingrid Adams, que ahora tiene 68 años, ha estado lidiando con el cáncer pulmonar metastásico durante más de una década. El tratamiento estándar, que incluye quimioterapia y radioterapia , mantuvo su enfermedad bajo control por un tiempo, pero el cáncer continuó diseminándose